Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

Stock Information for Immunome Inc.

Loading

Please wait while we load your information from QuoteMedia.